261 related articles for article (PubMed ID: 34721394)
1. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H
Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571
[TBL] [Abstract][Full Text] [Related]
3. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
4. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
[TBL] [Abstract][Full Text] [Related]
7. Teriflunomide and its mechanism of action in multiple sclerosis.
Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H
Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824
[TBL] [Abstract][Full Text] [Related]
8. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956
[No Abstract] [Full Text] [Related]
9. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.
Comi G; Miller AE; Benamor M; Truffinet P; Poole EM; Freedman MS
Mult Scler; 2020 Aug; 26(9):1083-1092. PubMed ID: 31172849
[TBL] [Abstract][Full Text] [Related]
10. An updated review of teriflunomide's use in multiple sclerosis.
Miller AE
Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
[TBL] [Abstract][Full Text] [Related]
11. Teriflunomide, a potential novel cause of chronic active colitis.
Kővári B; Zachs J; Murchie B; Lauwers GY
Histopathology; 2020 Dec; 77(6):1000-1001. PubMed ID: 32323888
[No Abstract] [Full Text] [Related]
12. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.
Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S
Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325
[TBL] [Abstract][Full Text] [Related]
13. Teriflunomide-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
Khurana D; Kaur G; Sendhil Kumaran M; Choudhary R; Ashraf R; Thakur V
Clin Exp Dermatol; 2021 Jan; 46(1):166-169. PubMed ID: 32557734
[No Abstract] [Full Text] [Related]
14. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study.
Lycke J; Farman H; Nordin A
CNS Drugs; 2023 Feb; 37(2):181-188. PubMed ID: 36729276
[TBL] [Abstract][Full Text] [Related]
16. Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients.
Medina S; Sainz de la Maza S; Villarrubia N; Álvarez-Lafuente R; Costa-Frossard L; Arroyo R; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
Ann Clin Transl Neurol; 2019 Feb; 6(2):355-363. PubMed ID: 30847367
[TBL] [Abstract][Full Text] [Related]
17. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
Papadopoulou A; Kappos L; Sprenger T
Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
[No Abstract] [Full Text] [Related]
19. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
Scott LJ
Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
[TBL] [Abstract][Full Text] [Related]
20. Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis.
Wu Q; Wang Q; Yang J; Mills EA; Chilukuri P; Saad A; Dowling CA; Fisher C; Kirch B; Mao-Draayer Y
Mult Scler Relat Disord; 2023 Jul; 75():104719. PubMed ID: 37172367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
